文献速递银屑病与炎症性皮肤病

利用经验证银屑病流行病学筛查工具在银屑病患者中识别银屑病关节炎症状与体征:基于美国Corrona银屑病登记处的横断面分析

Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2019-03-05

本研究基于美国Corrona银屑病登记处,纳入1516例银屑病患者,其中904例无皮肤科医生报告的银屑病关节炎。采用经验证的银屑病流行病学筛查工具(PEST)评估,112例(12.4%)PEST评分≥3分,提示可能存在未诊断的银屑病关节炎,且这些患者更常伴有甲银屑病、较差健康相关生活质量及活动受限。

要点

  • 在无皮肤科医生报告银屑病关节炎的904例银屑病患者中,12.4%PEST评分≥3分。
  • PEST评分≥3分者更常为女性、年龄较大、不工作、BMI较高、银屑病病程较长。
  • PEST评分≥3分者更常伴甲银屑病、较差健康状态、疼痛、疲劳及活动受限。

核心结论

  • 在银屑病患者中需要改进银屑病关节炎筛查,因为经验证的PEST识别出超过十分之一未被记录为银屑病关节炎的登记患者评分≥3分,这些患者可能存在未诊断的银屑病关节炎。
  • 适当的早期诊疗很重要,因为这些患者更可能伴有甲银屑病、较差的健康相关生活质量和较差的活动受限。

研究设计与样本

  • 基于美国Corrona银屑病登记处的横断面分析,纳入所有具有全部5个PEST问题数据的患者,共1516例银屑病患者,其中904例无皮肤科医生报告的银屑病关节炎。
  • 采用t检验比较连续变量、卡方检验比较分类变量,比较PEST评分≥3分与<3分患者的 demographics、临床特征和患者报告结局。

主要发现

  • 在904例无皮肤科医生报告银屑病关节炎的患者中,112例(12.4%)PEST评分≥3分。
  • PEST评分≥3分患者较<3分患者显著年龄更大、更多为女性、更少工作、BMI更高。
  • PEST评分≥3分患者银屑病病程显著更长,更常伴甲银屑病,健康状态、疼痛、疲劳、皮肤病生活质量指数和活动受限更差。

关键数值与推荐

  • PEST为五项问卷,评分≥3分可能提示银屑病关节炎。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite increasing awareness of the disease, rates of undiagnosed psoriatic arthritis (PsA) are high in patients with psoriasis (PsO). The validated Psoriasis Epidemiology Screening Tool (PEST) is a five-item questionnaire developed to help identify PsA at an early stage. OBJECTIVES: To assess the risk of possible undiagnosed PsA among patients with PsO and characterize patients based on PEST scores. METHODS: This study included all patients enrolled in the Corrona PsO Registry with data on all five PEST questions. Demographics, clinical characteristics and patient-reported outcomes were compared in Corrona PsO Registry patients with PEST scores ≥3 and <3 using t-tests for continuous variables and chi-squared tests for categorical variables; scores ≥3 may indicate PsA. RESULTS: Of 1516 patients with PsO, 904 did not have dermatologist-reported PsA; 112 of these 904 patients (12.4%) scored ≥3 and were significantly older, female, less likely to be working, and had higher BMI than patients with scores <3. They also had significantly longer PsO duration, were more likely to have nail PsO and had worse health status, pain, fatigue, Dermatology Life Quality Index and activity impairment. CONCLUSIONS: Improved PsA screening is needed in patients with PsO because the validated PEST identified over one-tenth of registry patients who were not noted to have PsA as having scores ≥3, who could have had undiagnosed PsA. Appropriate, earlier care is important because these patients were more likely to have nail PsO, worse health-related quality of life and worse activity impairment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Mease PJ, Palmer JB, Hur P, et al. Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis Registry. J Eur Acad Dermatol Venereol. 2019. PMID: 30663130. doi:10.1111/jdv.15443

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。